

Edgar Filing: ALKERMES INC - Form 8-K

ALKERMES INC
Form 8-K
July 01, 2002

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

DATE OF REPORT - JUNE 28, 2002
(Date of earliest event reported)

ALKERMES, INC.
(Exact name of Registrant as specified in its charter)

PENNSYLVANIA	0-19267	23-2472830
(State of incorporation)	(Commission file number)	(IRS employer identification number)

64 SIDNEY STREET, CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices, zip code)

AREA CODE (617) 494-0171
(Telephone number)

ITEM 5. OTHER INFORMATION.

On June 28, 2002, Johnson & Johnson Pharmaceutical Research & Development, LLC, ("J&J PRD"), an affiliate of Janssen Pharmaceutica, Inc., a collaborative partner of Alkermes, Inc., a Pennsylvania corporation ("Alkermes"), received a non-approvable letter from the U.S. Food and Drug Administration (the "FDA") related to the New Drug Application for Risperdal Consta(TM), a long-acting formulation of Risperdal (R) utilizing Alkermes' Medisorb(R) technology.

A copy of the press release issued by Alkermes on July 1, 2002, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

99.1 Press Release issued by Alkermes, Inc., dated July 1, 2002.

Edgar Filing: ALKERMES INC - Form 8-K

2

SIGNATURES

Pursuant to requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 1, 2002

Alkermes, Inc.

By: /s/ James M. Frates

James M. Frates
Vice President, Chief Financial
Officer, and Treasurer

3

ALKERMES, INC.

CURRENT REPORT ON FORM 8-K

EXHIBIT INDEX

Exhibit No.

Exhibit

99.1

Press Release issued by Alkermes, Inc., dated July 1, 2002.

4